Literature DB >> 12809878

Estimated economic costs of overactive bladder in the United States.

Teh-Wei Hu1, Todd H Wagner, Judith D Bentkover, Kristi LeBlanc, Amy Piancentini, Walter F Stewart, Ron Corey, Steve Z Zhou, Timothy L Hunt.   

Abstract

OBJECTIVES: To estimate the economic costs of overactive bladder (OAB), including community and nursing home residents, and to compare the costs in male versus female and older versus younger populations.
METHODS: The National Overactive Bladder Evaluation Program included a representative telephone survey of 5204 community-dwelling adults 18 years and older in the United States and a follow-up postal survey of all individuals with OAB identified and age and sex-matched controls. The postal survey asked respondents about bladder symptoms, self-care use, treatment use, work loss, and OAB-related health consequences. Survey data estimates were combined with year 2000 average cost data to calculate the cost of OAB in the community. Institutional costs were estimated from the costs of urinary incontinence in nursing homes, limited to only those with urge incontinence or mixed incontinence (urge and stress).
RESULTS: The estimated total economic cost of OAB was 12.02 billion dollars in 2000, with 9.17 and 2.85 billion dollars incurred in the community and institutions, respectively. Community female and male OAB costs totaled 7.37 and 1.79 billion dollars, respectively. The estimated total cost was sensitive to the estimated prevalence of OAB; therefore, we calculated the average cost per community-dwelling person with OAB, which was 267 dollars per year.
CONCLUSIONS: By quantifying the total economic costs of OAB, this study-the first obtained from national survey data-provides an important perspective of this condition in society. The conservative estimates of the total cost of OAB were comparable to those of osteoporosis and gynecologic and breast cancer. Although this provides information on the direct and indirect costs of OAB, quality-of-life issues must be taken into account to gain a better understanding of this condition.

Entities:  

Mesh:

Year:  2003        PMID: 12809878     DOI: 10.1016/s0090-4295(03)00009-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  67 in total

Review 1.  Male overactive bladder: the role of urodynamics and anticholinergics.

Authors:  Scott MacDiarmid; Alexandra Rogers
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

2.  Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

Authors:  Rodney U Anderson; Scott MacDiarmid; Sherron Kell; James H Barada; Scott Serels; Roger P Goldberg
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-05-03

3.  The Burden of Overactive Bladder on US Public Health.

Authors:  W Stuart Reynolds; Jay Fowke; Roger Dmochowski
Journal:  Curr Bladder Dysfunct Rep       Date:  2016-01-23

Review 4.  Hyperoxaluria-induced oxidative stress and antioxidants for renal protection.

Authors:  Saeed R Khan
Journal:  Urol Res       Date:  2005-11-15

Review 5.  [Not Available].

Authors:  Abdelmounaim Qarro; Mohammed Asseban; Khalil Bazine; Mohammed Najoui; Jamaleddine Samir; Youssef Ouhbi; Amoqrane Beddouch; Mohammed Lezrek; Mohammed Alami
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

Review 6.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia.

Authors:  Scott A MacDiarmid
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

8.  Prevalence, evaluation and management of overactive bladder in primary care.

Authors:  Wellman W Cheung; Nadia H Khan; Karmina K Choi; Martin H Bluth; Miriam T Vincent
Journal:  BMC Fam Pract       Date:  2009-01-23       Impact factor: 2.497

9.  Oxybutynin extended release for the management of overactive bladder: a clinical review.

Authors:  A M Arisco; E K Brantly; S R Kraus
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

10.  Tolterodine extended release is well tolerated in older subjects.

Authors:  T L Griebling; S R Kraus; H E Richter; D B Glasser; M Carlsson
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.